The use of statins in patients with manifest cardiovascular disease is established, with similar benefits seen in women and men, but statin use for the primary prevention of cardiovascular disease is controversial, particularly for women. We analyzed sex-specific outcomes in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and conducted an updated meta-analysis of statin use for women in primary prevention (20 147 women; Ͼ276 cardiovascular disease events; mean age, 63 to 69 years). JUPITER was a multicenter randomized trial designed to assess the benefits and risks of statin therapy in apparently healthy individuals selected on the basis of elevated high-sensitivity C-reactive protein, a marker of higher cardiovascular risk, without a concomitant elevation in low-density lipoprotein cholesterol. JUPITER participants included 6801 women Ն60 years of age and 11 001 men Ն50 years of age with high-sensitivity C-reactive protein Ն2 mg/L and low-density lipoprotein cholesterol Ͻ130 mg/dL who were randomized to rosuvastatin 20 mg/d versus placebo. Absolute cardiovascular disease rates for rosuvastatin and placebo in JUPITER were lower for women than for men, but there were similar and significant relative risk reductions in both women (by 46%) and men (by 42%). In women, there was significant reduction in revascularization/unstable angina and nonsignificant reductions in other components of the primary end point. Furthermore, in this updated meta-analysis of statin therapy for primary prevention in women, statin allocation yielded a significant relative risk reduction in cardiovascular disease by one-third, similar to prior results in men and in secondary prevention in women. See p 1069.
Ethnic Differences in Physiological Cardiac Adaptation to Intense Physical Exercise in Highly Trained Female Athletes
The investigators provide novel data on physiological cardiac adaptation in highly trained female black athletes. Existing data relating to ethnic differences in exercise-related cardiovascular adaptation are confined to men and indicate a racial predilection to the development of substantial left ventricular hypertrophy and marked repolarization changes in black athletes that may overlap with hypertrophic cardiomyopathy. This study of 240 normotensive, nationally ranked black female athletes and 200 nationally ranked white athletes participating in 10 different sporting disciplines reveals that black women also exhibit greater magnitude of left ventricular hypertrophy and higher prevalence of repolarization anomalies than their white counterparts. Three percent of black athletes showed a left ventricular wall thickness Ͼ11 mm (12 to 13 mm) compared with none of the white athletes, and almost 15% demonstrated repolarization changes, including deep T-wave inversions, compared with only 2% of white athletes. In contrast to most individuals with hypertrophic cardiomyopathy, none of the black athletes exhibited a left ventricular wall thickness Ͼ13 mm or deep T-wave inversions in contiguous inferior/lateral leads, which indicates that such observations in black female athletes warrant further investigation. Application of standardized criteria derived from white athletes for differentiation of physiological adaptation from hypertrophic cardiomyopathy has the potential to result in unnecessary investigation and unfair disqualification from sport in black athletes. The study is clinically relevant in facilitating the differentiation of physiological adaptation from morphologically mild hypertrophic cardiomyopathy in black female athletes exhibiting left ventricular hypertrophy, particularly in countries where black individuals represent a high proportion of athletes competing at regional and national levels. See p 1078.
Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure
Previous studies have suggested that monitoring of ambulatory hemodynamics may improve outcomes in chronic heart failure. We conducted a prospective, observational, first-in-human study of a physician-directed patient self-management system targeting left atrial pressure (LAP). In this study, patients with reduced or preserved left ventricular ejection fractions and a history of New York Heart Association class III to IV heart failure and acute decompensation were implanted with an investigational LAP monitor, and readings were acquired twice daily. For the first 3 months, patients and clinicians were blinded to these readings, and treatment continued per usual clinical assessment. Thereafter, LAP readings and individualized therapy instructions guided by these pressures were displayed to the patient. Event-free survival without decompensation was 61% at 3 years, and events tended to be more favorable after the first 3 months once therapy was being guided by daily LAP readings. Mean daily LAP fell in the first 3 months during pressure-guided therapy. The frequency of elevated readings (Ͼ25 mmHg) was reduced significantly during LAP-guided therapy, and there were improvements in New York Heart Association class and left ventricular ejection fraction. Doses of angiotensinconverting enzymes/angiotensin-receptor blockers and ␤-blockers were uptitrated significantly, by 37% and 40%, respectively, whereas there was a trend to lower doses of loop diuretics. These findings suggest that physician-directed patient self-management of LAP has the potential to improve hemodynamics, symptoms, and outcomes in advanced heart failure. Hemodynamic monitoring may guide more optimal dosing with proven neurohormonal antagonist therapies. See p 1086.
Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both
Mechanical dyssynchrony has been considered an independent predictor for adverse outcomes in patients with heart failure. However, its importance after myocardial infarction is not well understood. We assessed the influence of mechanical dyssynchrony on clinical outcomes in 381 patients with left ventricular dysfunction, heart failure, or both after acute myocardial infarction. Dyssynchrony severity at baseline was associated with older age; hypertension; history of myocardial infarction, heart failure, and longer QRS duration; less percutaneous coronary angioplasty; greater left ventricular and left atrial volumes, left ventricular mass index, infarct length, and mitral regurgitation; and lower left ventricular ejection fraction. Moreover, we observed the independent prognostic value of mechanical dyssynchrony in predicting death or heart failure in this 1061
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Original Research Put Into Perspective for the Practicing Clinician Volume 121 Ⅲ Number 9 Ⅲ March 9, 2010 population. These data suggest that the contractile pattern itself may play a role in prognosis after myocardial infarction independently of global and regional contractile function. See p 1096.
Notch Signaling Regulates Endothelial Progenitor Cell Activity During Recovery From Arterial Injury in Hypercholesterolemic Mice
Abundant evidence has linked hypercholesterolemia with the advent and progression of atherosclerosis. To facilitate the study of the mechanisms by which hypercholesterolemia leads to atherosclerosis, animal models have been developed. Most notably, the apolipoprotein E (ApoE)-null and low-density lipoprotein receptor-null mice have been used extensively in attempts to gain a better understanding of the effects of high lipid levels on atheroma formation. In recent years, traditional cardiovascular risk factors have also been associated with decreased numbers of circulating endothelial progenitor cells (EPCs), which have been suggested to participate in endothelial repair and maintenance. Ample experimental evidence suggests that EPCs are mobilized from the bone marrow to the peripheral circulation after arterial injury (eg, percutaneous transluminal coronary angioplasty or stent implantation) and promote reendothelialization at the injury site, thereby speeding endothelial recovery and reducing the risk of restenosis and atherosclerotic plaque formation. Here, we compared EPC recruitment, reendothelialization, and plaque formation after carotid artery injury in wild-type mice and ApoE Ϫ/Ϫ mice. Our findings indicate that EPC recruitment was higher in ApoE Ϫ/Ϫ mice than in wild-type mice and that the enhanced recruitment likely evolves through a moderate decline in Notch expression. Reendothelialization was also greater in ApoE Ϫ/Ϫ mice, which was somewhat surprising because ApoE Ϫ/Ϫ mice are prone to atherosclerosis. Furthermore, transplanted, bone-marrow-derived EPCs were found at the border of the atherosclerotic lesions, which could suggest that EPCs contribute to the early stage of plaque formation. However, the clinical implications of these observations must be interpreted with caution, particularly because circulating EPC levels were higher in ApoE Ϫ/Ϫ mice than in wild-type mice, whereas hypercholesterolemia, hypertension, and many other risk factors for cardiovascular disease are associated with declines in human EPC levels. Collectively, our findings emphasize the need for additional experiments in other hypercholesterolemic animal models and underscore the potential for genetic mouse models of human disease to yield data that do not necessarily reflect clinical reality. To clarify the paradoxical observation on the direct effect of cholesterol on EPC contribution to reendothelialization versus plaque formation in Apo E knockout mice after arterial injury, further investigations using different types of hypercholesterolemic animals and, importantly, additional clinical correlation are required. See p 1104.
Functional Mesenchymal Stem Cells Derived From Human Induced Pluripotent Stem Cells Attenuate Limb Ischemia in Mice
Despite the initial encouraging results of preclinical and clinical studies, mesenchymal stem cells (MSCs) derived from adult tissue such as bone marrow have a limited proliferation and differentiation potential for tissue repair in ischemic disease. More important, aging significantly impairs their survival and differentiation potential and thus limits their therapeutic efficacy. Recent breakthrough in the generation of induced pluripotent stem cells (iPSCs) offers the possibility to obtain a high yield of patient-specific MSCs. In this study, we demonstrate that functional MSCs can be directly generated from iPSCs (iPSC-MSCs). Transplantation of iPSC-MSCs into mice achieved a more beneficial effect than adult bone marrowderived MSCs in the attenuation of severe limb ischemia. This greater potential of iPSC-MSCs may be attributable to their superior survival and engraftment via de novo vascular and muscle differentiation and paracrine mechanisms. Our study suggests that functional MSCs can be generated from human iPSCs and have the potential to treat ischemic disease in a patient-specific, cost-effective, and batch-to-batch-consistent manner. See p 1113.
CD137 (4 -1BB) Deficiency Reduces Atherosclerosis in Hyperlipidemic Mice
The tumor necrosis factor receptor superfamily, which includes CD40, OX40, and LIGHT, plays important roles in atherogenesis. CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, has been reported to be expressed in human atherosclerotic lesions. In this study, we show that CD137 deficiency leads to attenuation of atherosclerosis in 2 different mouse atherosclerosis models. We propose a model mechanism for the roles of CD137/ CD137 ligand signaling in atherosclerosis on the basis of the results of the present study. CD137/CD137 ligand signaling can induce activation of macrophages and lymphocytes through its bidirectional signaling. Endothelial CD137 activation also can induce the production of monocyte chemoattractant protein-1 and cell adhesion molecules, which leads to enhanced monocyte attachment to endothelium. Taken together, the blocking of CD137/CD137 ligand signaling can reduce atherosclerosis by attenuating the immune responses in lymphocytes, macrophages, and endothelial cells. Our results suggest that CD137 can be an effective therapeutic target for the development of antiatherogenic drugs. See p 1124.
